When genomic and standard test results diverge: implications for breast cancer patients' preference for chemotherapy

Purpose We examined how women incorporate potentially differing genomic and standard assessments of breast cancer recurrence risk into chemotherapy decisions. Methods 165 women previously treated for early-stage breast cancer indicated their interest in chemotherapy regimens to prevent recurrence of...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research and treatment 2009-09, Vol.117 (1), p.25-29
Main Authors: Brewer, Noel T, Edwards, Alrick S, O'Neill, Suzanne C, Tzeng, Janice P, Carey, Lisa A, Rimer, Barbara K
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - genetics
Breast Neoplasms - pathology
Cancer research
Cancer therapies
Chemotherapy
Decision Making
Female
Genetic Predisposition to Disease
Genetic Testing - methods
Genomics
Gynecology. Andrology. Obstetrics
Humans
Mammary gland diseases
Medical sciences
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Recurrence, Local - genetics
Oncology
Patient Satisfaction
Patients
Preclinical Study
Preferences
Risk Factors
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose We examined how women incorporate potentially differing genomic and standard assessments of breast cancer recurrence risk into chemotherapy decisions. Methods 165 women previously treated for early-stage breast cancer indicated their interest in chemotherapy regimens to prevent recurrence of breast cancer in response to six hypothetical vignettes that presented breast cancer recurrence risk estimates from standard criteria and a genomic test, some of which were discordant. Results Standard and genomic test results each elicited greater interest in chemotherapy when they indicated high rather than low risk for recurrence (89% vs. 26%, and 87% vs. 22%, respectively, Ps < 0.001). Genomic test results had a larger impact on chemotherapy preferences than standard measures to predict recurrence. Conclusions Some women may be reluctant to forgo chemotherapy when genomic tests indicate low recurrence risk but standard criteria suggest high risk. Additional research including replication of the findings of this small, vignette-based study is needed.
ISSN:0167-6806
1573-7217
DOI:10.1007/s10549-008-0175-2